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DrOBJECTIVES This study assessed clinical events and patient-reported chest pain 2 years after treatment of all-comers
with Resolute Integrity zotarolimus-eluting stents (Medtronic Vascular, Santa Rosa, California) and Promus Element
everolimus-eluting stents (Boston Scientiﬁc, Natick, Massachusetts).
BACKGROUND For both drug-eluting stents (DES), no all-comer outcome data from >12 months of follow-up have
been published. Although there is increasing interest in patient-reported chest pain following stenting, data with novel
DES are scarce.
METHODS The DUTCH PEERS multicenter trial (TWENTE II) (DUrable Polymer-Based STent CHallenge of Promus
ElemEnt Versus ReSolute Integrity) Randomized Trial [TWENTE II]) randomized 1,811 all-comer patients to treatment
with 1 type of DES. Monitoring and event adjudication were performed by independent contract research organizations.
RESULTS The 2-year follow-up of 1,810 patients (99.9%) was available. The primary composite endpoint target vessel
failure occurred in 8.6% and 7.8% of patients treated with zotarolimus- and everolimus-eluting stents, respectively
(p ¼ 0.55). Rates of components of target vessel failure were: cardiac death (2.4% vs. 1.9%, p ¼ 0.42); target vessel–
related myocardial infarction (2.4% vs. 1.8%, p ¼ 0.33); clinically-indicated target vessel revascularization (4.6% vs.
4.9%, p ¼ 0.83). At 1- and 2-year follow-up, >80% of patients were free from chest pain (no between-stent difference).
In addition, >87% of patients were either free from chest pain or experienced pain only at maximal physical exertion, but
not during normal daily activities. Patients with chest pain after 12 months at no more than moderate physical effort had
a higher risk of target vessel revascularization during the following year (hazard ratio: 1.89 [95% conﬁdence interval:
1.05 to 3.39], p ¼ 0.03).
CONCLUSIONS During the second year of follow-up, the incidence of adverse clinical endpoints remained similar and
low for both DES. The vast majority of patients were free from chest pain. (J Am Coll Cardiol Intv 2015;8:889–99)
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890D rug-eluting stents (DES) have re-volutionized the treatment of ob-structive coronary disease. Since
their introduction, these devices have un-
dergone major improvements (1). These in-
clude an increase in biocompatibility of
their durable polymer-based coatings in
the second-generation DES (2,3) and an im-
provement in ﬂexibility and deliverability
of their metallic stent platforms in the more
recent generation of DES, using the same
coatings (4–6).
The cobalt-chromium–based Resolute
Integrity zotarolimus-eluting stent (ZES)
(Medtronic, Santa Rosa, California) andthe platinum-chromium–based Promus Element
everolimus-eluting stent (EES) (Promus Element,
Boston Scientiﬁc, Natick, Massachusetts) are 2 such
novel, highly-ﬂexible DES, which have recently been
compared in the randomized, multicenter DUTCH
PEERS trial (DUrable Polymer-Based STent CHal-
lenge of Promus ElemEnt Versus ReSolute Integrity)
Randomized Trial [TWENTE II]) in all-comers (4).
DUTCH PEERS is the ﬁrst randomized trial that re-
ports outcome data of Resolute Integrity ZES and the
ﬁrst trial to provide a head-to-head comparison of
the 2 durable coating-based DES, showing low clin-
ical event rates at 1 year (4). Follow-up information
after the cessation of dual-antiplatelet therapy
(DAPT) at 1 year is of interest to demonstrate or
exclude any potential late catch-up in adverse
events.
In the presence of very low rates of traditional
clinical endpoints following percutaneous coronary
interventions (PCIs) with novel DES (4–6), there is
growing interest in the assessment of patient-
reported chest pain—the principal anginal symptom
and main trigger of repeat cardiac assessment de-
spite a successful PCI (7,8). Moreover, long-lasting
absence of chest pain determines to a great extent
the “patient satisfaction” with PCI. Therefore, in the
present 2-year analysis of the DUTCH PEERS all-
comers population, we investigated both clinical
event rates and patient-reported chest pain following
treatment with Resolute Integrity ZES and Promus
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STUDY DESIGN, PATIENTS, AND PROCEDURES.
The DUTCH PEERS trial has previously been described
in detail (4). In brief, DUTCH PEERS is a multicenter,
prospective, randomized, single-blinded, investi-
gator-initiated trial in an all-comers patient popula-
tion. Study enrollment was performed between
November 25, 2010, and May 24, 2012. There was no
limit for lesion length, reference size, and number of
lesions or diseasedvessels to be treated. Interventional
procedures were performed according to standard
techniques and routine clinical protocols. The study
complied with the Declaration of Helsinki and was
approved by the Medical Ethics Committee Twente
and the institutional review boards of all partici-
pating centers. All patients provided written informed
consent. Patients were randomly assigned, in a 1:1
fashion, to treatment with 1 of the 2 study stents.
Resolute Integrity ZES releases zotarolimus from
the 6 mm BioLinx conformal, permanent polymer sys-
tem (blend of 3 polymers), which has been highly
effective on Resolute stents (2,3,9), and uses the
novel, sinusoid-shaped, single cobalt-chromium wire-
based, open-cell design Integrity stent platform
(91-mm round struts) (4) with slightly more strut con-
nections in close vicinity to its proximal and distal
ends. Promus Element EES releases everolimus from a
7-mm conformal, permanent ﬂuoropolymer coating
that recently demonstrated its efﬁcacy in other patient
populations (2,3,9–12) and uses the novel, laser-
cut, platinum-chromium alloy (highly radiopaque),
open-cell design (serpentine rings connected by
links) Element stent platform (81-mm struts) for im-
proved deliverability (4,13,14). Novel ﬂexible, highly-
deliverable stents may be less longitudinally stable,
which can sometimes result in a distortion or short-
ening of an initially successfully-implanted stent in
the longitudinal axis; differences in stent design and
radiographic visibility may explain between-stent
differences. In DUTCH PEERS, a dedicated angio-
graphic analysis conﬁrmed the presence of longitudi-
nal stent deformations in 1% of patients treated with
Promus Element (no clinical consequences up to 1-
year follow-up) and in none of the patients treated
with Resolute Integrity (4).nic; has received lecture fees from Boston Scientiﬁc,
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891Interventions were performed according to stan-
dard techniques. Patients were pre-treated with ace-
tylsalicylic acid and clopidogrel. Lesion pre-dilation,
use of glycoprotein IIb/IIIa receptor antagonists,
direct stenting, and stent post-dilation were left to
the operator’s discretion. Operators were requested
to report evident (or suspected) longitudinal stent
deformation, deﬁned as distortion or shortening of
initially successfully-implanted stents in the longi-
tudinal axis (15,16). In general, dual-antiplatelet
therapy was prescribed for 1 year. Systematic labora-
tory and electrocardiographic testing were performed
as previously described (4) to identify periprocedural
myocardial infarction (MI).
The follow-up procedures of the study have pre-
viously been reported (4,17). At 1- and 2-year follow-
up, research nurses and analysts who were blinded
to the assigned stent type obtained information on
chest pain by use of a medical questionnaire or, in the
absence of a response, a telephone follow-up that
used the same questions.
Angiographic analysts, blinded to the stent type
used, performed off-line quantitative coronary angi-
ography according to current standards (QAngio XA
7.2, Medis, Leiden, the Netherlands). The CRO Cardio
Research Enschede (Enschede, the Netherlands) co-
ordinated the trial and data management. Regular
safety data were reported to the independent Med-
ical Ethics Committee Twente. Data monitoring was
performed by the independent contract research or-
ganization Diagram (Zwolle, the Netherlands). Pro-
cessing of clinical outcome data and clinical event
adjudication were performed by the independent
contract research organization Cardialysis (Rotter-
dam, the Netherlands).
DEFINITION OF CLINICAL ENDPOINTS. Deﬁnitionsof
all pre-deﬁned clinical endpoints have previously been
described in detail (4,17). Clinical endpoints were
deﬁned according to the Academic Research Con-
sortium, including the addendum on MI (4,17–19). In
brief, target vessel failure (TVF), the primary endpoint
of DUTCH PEERS, is a composite of cardiac death,
target vessel–related MI, or clinically-indicated target
vessel revascularization (TVR). Death was considered
cardiac unless an unequivocal noncardiac cause could
be established. MI was deﬁned by any creatine kinase
concentration of more than double the upper limit of
normalwithelevatedconﬁrmatory cardiacbiomarkers.
Atargetvessel–relatedMIwasrelatedtothetargetvessel
or couldnotbe related toanothervessel. TVRand target
lesion revascularization (TLR) were considered clini-
cally indicated if the angiographic diameter stenosis
was $70%, or $50% in the presence of ischemic signsor symptoms. Stent thrombosis was classiﬁed ac-
cording to the Academic Research Consortium deﬁni-
tions (19,20).
Pre-deﬁned secondary endpoints included the
components of the primary endpoint, all-cause mor-
tality, any MI, clinically-indicated TLR, stent throm-
bosis, and longitudinal stent deformation. Other
composite parameters were (in hierarchical order):
target lesion failure, a composite of cardiac death,
target vessel–related MI, or clinically-indicated TLR;
major adverse cardiac events, a composite of all-cause
death, any MI, emergent coronary bypass surgery, or
clinically-indicated TLR; and patient-oriented com-
posite endpoint, a composite of all-cause death, any
MI, or any coronary revascularization. An exploratory
subgroup analysis of the primary endpoint was per-
formed in line with previous trials (2,3).
Patient-reported chest pain, the principal symptom
of angina pectoris and a surrogate for myocardial
ischemia, was classiﬁed into 4 scores: 0 ¼ no chest
pain at all; 1 ¼ chest pain only during most severe
physical exertion; 2 ¼ chest pain at moderate physical
effort (during moderate/normal daily activities); and
3 ¼ chest pain at mild physical effort or at rest.
STATISTICAL ANALYSIS. Data were reported as fre-
quencies and percents for dichotomous and categor-
ical variables and as mean  SD for continuous
variables. Differences in dichotomous and categorical
variables were assessed with the chi-square or Fisher
exact tests, whereas continuous variables were as-
sessed with the Student t test or the Wilcoxon rank
sum test, as appropriate. The Kaplan-Meier analysis
was used to calculate the time to clinical endpoints,
and the log-rank test was applied to compare
between-group differences. A landmark analysis was
performed at 1 year for various adverse clinical events
expressed as a difference in proportion and 95%
conﬁdence interval (CI) (21). The Cox proportional-
hazards regression analysis was performed to test
for interaction between subgroups and stent type
with regard to the clinical endpoint TVF. All p values
and CIs were 2-sided, and a p value <0.05 was
considered signiﬁcant. Data analysis was performed
with SPSS version 17 (SPSS Inc., Chicago, Illinois) and
SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina).
RESULTS
A total of 1,811 patients were randomly assigned to
treatment with the Resolute Integrity ZES (n ¼ 906) or
Promus Element EES (n ¼ 905). The main clinical,
procedural, and angiographic characteristics of both
TABLE 1 Characteristics of Patients, Target Lesions, and Interventional Procedures
Resolute Integrity
ZES
Promus Element
EES
p
Value
Patient Data
n 906 905
Age, yrs 63.9  10.6 63.9  11.0 0.97
Men 665 (73.4) 675 (72.6) 0.70
Diabetes mellitus (any) 167 (18.4) 157 (17.3) 0.55
Arterial hypertension 500 (55.2) 484 (53.5) 0.47
Hypercholesterolemia 418 (46.1) 430 (47.5) 0.56
Current smoker* 213 (23.6) 231 (25.5) 0.34
Family history of CAD† 452 (50.0) 451 (50.0) 0.98
Previous myocardial infarction 207 (22.8) 190 (21.0) 0.34
Previous percutaneous coronary
intervention
182 (20.1) 167 (18.5) 0.38
Previous coronary bypass surgery 84 (9.3) 89 (9.8) 0.68
Clinical syndrome at presentation 0.07
Stable angina pectoris 372 (41.1) 377 (41.7)
Unstable angina pectoris 113 (12.5) 132 (14.6)
Non–ST-segment elevation
myocardial infarction
246 (27.2) 201 (22.2)
ST-segment elevation myocardial
infarction
175 (19.3) 195 (21.5)
At least 1 small vessel (RVD <2.75 mm) 551 (60.8) 517 (57.1) 0.11
At least 1 lesion length >27 mm 161 (17.8) 157 (17.3) 0.81
At least 1 chronic total occlusion 38 (4.2) 38 (4.2) 1.00
Glycoprotein IIb/IIIa antagonist 262 (28.9) 259 (28.6) 0.89
Number of lesions treated per patient 0.32
1 lesion treated 668 (73.7) 688 (76.0)
2 lesions treated 191 (21.1) 182 (20.1)
3 or more lesions treated 47 (5.2) 35 (3.9)
Lesions and Interventional Procedures Data
Lesions, n 1,205 1,166
ACC/AHA lesion class B2/C 793 (65.8) 765 (65.6) 0.92
De novo lesion‡ 1,147 (95.2) 1,103 (94.6) 0.51
Reference vessel diameter, mm 2.68  0.59 2.70  0.59 0.32
Implantation of assigned stents only 1,195 (99.2) 1,161 (99.6) 0.22
Number of stents per lesion 1.35  0.68 1.36  0.70 0.70
Total stent length per lesion, mm 28.60  18.51 29.71  19.11 0.15
Direct stenting 352 (29.2) 326 (28.0) 0.50
Stent post-dilation 887 (73.6) 920 (78.9) <0.01
Values are n, mean  SD, or n (%). *Of 903 patients in the zotarolimus-eluting stent group and 905 patients in
the everolimus-eluting stent group. †Of 903 patients in the zotarolimus-eluting stent group and 902 patients in
the everolimus-eluting stent group. ‡Including chronic total occlusion, but not grafts or in-stent restenosis.
ACC/AHA¼ American College of Cardiology/American Heart Association; CAD ¼ coronary artery disease; EES¼
everolimus-eluting stent(s); RVD ¼ reference vessel diameter; ZES ¼ zotarolimus-eluting stent(s).
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892study groups are summarized in Table 1. The 2-year
follow-up data was obtained from all but 1 patient,
who withdrew consent (Online Figure 1 shows trial
consort diagram).
RATES OF ADVERSE CLINICAL EVENTS. At 2-year
follow-up, the composite primary endpoint TVF
occurred in 78 patients (8.6%) treated with Resolute
Integrity ZES and in 71 patients (7.8%) treated with
Promus Element EES (p ¼ 0.55) (Table 2, Figure 1). Theincidence of the individual components of TVF was
similar for both stent arms: cardiac death (2.4% vs.
1.9%, p ¼ 0.42); target vessel–related MI (2.4%
vs. 1.8%, p ¼ 0.33); and clinically-indicated TVR (4.6%
vs. 4.9%, p ¼ 0.83).
An exploratory subgroup analysis revealed no sig-
niﬁcant between-stent difference in TVF at 2 years
across various subgroups (Figure 2). In addition, there
was also no signiﬁcant difference in various event
rates between 1- and 2-year follow-up (Table 3). None
of the 9 patients who had developed longitudinal
stent deformation in Promus Element EES during the
index PCI procedure experienced an adverse clinical
event during the second year of follow-up, although
DAPT was discontinued after 12 months in all but
1 patient, who continued DAPT at physician discre-
tion (Online Table 1).
The incidence of deﬁnite-or-probable stent
thrombosis was 1.1% for both DES at 2-year follow-
up (Figure 3), and the rate of deﬁnite stent throm-
bosis was similar in patients treated with Resolute
Integrity ZES and Promus Element EES (0.8% vs.
0.9%, p ¼ 0.80) (Table 2). Very late deﬁnite stent
thrombosis occurred in 4 (0.4%) versus 2 (0.2%)
patients, respectively. At 2-year follow-up, 8.9% (78
of 872) and 9.0% (79 of 881) of the (surviving) pa-
tients in both stent arms were still on DAPT (Online
Table 2).
PATIENT-REPORTED CHEST PAIN. At 1-year follow-up,
1,647 (92.7%) of all 1,776 surviving patients provided
information about the presence or absence of chest
pain (Figure 4A). Most of these patients had no chest
pain at all, and there was no difference between stent
arms (81.6% vs. 81.0%, p ¼ 0.96). In addition, 88.2%
and 87.4% of patients in both stent arms had either no
chest pain at all or chest pain only during maximal
exertion (p ¼ 0.96). Patients with a chest pain score of
2 or 3 at 1-year follow-up had an almost 2-fold in-
crease in risk of clinically-indicated TVR during the
second year of follow-up (hazard ratio: 1.89 [95% CI:
1.05 to 3.39], p ¼ 0.03) compared with those with a
chest pain score of 0 or 1.
Chest pain data at 2-year follow-up was available
from 1,606 of 1,753 (91.6%) of the surviving patients
with pain scores that were similar to 1-year follow-
up (Figure 4B). At 2-year follow-up, new-onset (as
compared to 1-year) chest pain was reported by
8.8% of patients. Between 1- and 2-year follow-up,
77.9% (of the 1,572 patients who were alive at 2
years and answered the chest pain questionnaire at
both 1 and 2 years) in both stent arms showed no
change in chest pain score (Figure 4C), whereas only
10.6% and 12.2% of patients in the respective stent
TABLE 2 2-Year Clinical Outcome in Treatment Arms
Total Patients
(n ¼ 1,810)
Resolute
Integrity ZES
(n ¼ 905)
Promus
Element EES
(n ¼ 905)
Relative Risk
(95% CI) p Value
Death
Any cause 57 (3.1) 33 (3.6) 24 (2.7) 1.38 (0.82–2.31) 0.23
Cardiac cause 39 (2.2) 22 (2.4) 17 (1.9) 1.29 (0.69–2.42) 0.42
Target vessel–related myocardial infarction
Any 38 (2.1) 22 (2.4) 16 (1.8) 1.38 (0.73–2.60) 0.33
Q-wave 10 (0.6) 5 (0.6) 5 (0.6) 1.00 (0.29–3.44) 1.00
Non–Q-wave 28 (1.5) 17 (1.9) 11 (1.2) 1.55 (0.73–3.28) 0.34
Periprocedural (<48 h from index procedure) 30 (1.7) 19 (2.1) 11 (1.2) 1.74 (0.83–3.61) 0.14
Target vessel revascularization
Any 88 (4.9) 43 (4.8) 45 (5.0) 0.96 (0.64–1.44) 0.83
Clinically indicated 86 (4.8) 42 (4.6) 44 (4.9) 0.96 (0.63–1.44) 0.83
Target lesion revascularization,
clinically indicated
66 (3.6) 34 (3.8) 32 (3.5) 1.06 (0.66–1.71) 0.80
Target vessel failure* 149 (8.2) 78 (8.6) 71 (7.8) 1.10 (0.81–1.50) 0.55
Target lesion failure† 131 (7.2) 71 (7.8) 60 (6.6) 1.18 (0.85–1.65) 0.32
Major adverse cardiac events‡ 156 (8.6) 83 (9.2) 73 (8.1) 1.14 (0.84–1.54) 0.40
Patient-oriented composite endpoint§ 228 (12.6) 114 (12.6) 114 (12.6) 1.00 (0.78–1.27) 0.99
Stent thrombosis
Deﬁnite, any (0–720 days) 15 (0.8) 7 (0.8) 8 (0.9) 0.88 (0.32–2.40) 0.80
Deﬁnite, very late (360–720 days) 6 (0.3) 4 (0.4) 2 (0.2) 2.00 (0.37–10.89) 0.69
Deﬁnite or probable, any (0–720 days) 20 (1.1) 10 (1.1) 10 (1.1) 1.00 (0.42–2.39) 1.00
Deﬁnite or probable, very late (360–720 days) 7 (0.4) 5 (0.6) 2 (0.2) 2.50 (0.49–12.85) 0.45
Deﬁnite, probable, or possible, any (0–720 days) 46 (2.5) 23 (2.5) 23 (2.5) 1.00 (0.57–1.77) 1.00
Values are n (%). *Primary target vessel failure is a composite of cardiac death, target vessel-related myocardial infarction, or clinically-indicated target vessel revascularization.
†Target lesion failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically-indicated target lesion revascularization. ‡Major adverse cardiac
events is a composite endpoint of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, or clinically-indicated target lesion revascularization.
§Patient-oriented composite endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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893arms reported an increase and 11.6% and 9.9%
a decrease (p ¼ 0.30). Restricting the analysis of
chest pain score at 1 and 2 years to patients who
provided chest pain information at both times
(Online Figure 2) led to results that were similar to
ﬁndings in all responding patients at the individual
times of follow-up (Figures 4A and 4B).DISCUSSION
At 2-year follow-up of the DUTCH PEERS trial, the
incidence of the primary endpoint TVF was low and
similar in both stent arms. The rates of cardiac death,
target vessel–related MI, and clinically-indicated TVR
(i.e., the individual components of TVF), were also
low and similar. In addition, despite enrollment of an
all-comers population that included many high-risk
patients and complex lesions, the incidence of very
late stent thrombosis was extremely low. None of
the few patients who initially had developed longi-
tudinal stent deformation in Promus Element arm
experienced a very late clinical event after cessation
of DAPT.At 1- and 2-year follow-up, >80% of patients in
both stent arms were free from chest pain. In addi-
tion, >87% were either symptom-free or experienced
chest pain only at the very maximal level of physical
exertion, in that the pain did not limit the daily ac-
tivities of this large group of patients.
PREVIOUS DES TRIALS WITH THE EXAMINED STENTS.
The present analysis from the DUTCH PEERS ran-
domized trial is the ﬁrst report of 2-year clinical
outcome data in all-comers treated with the Resolute
Integrity or Promus Element stents. The PLATINUM
trial (A Prospective, Randomized, Multicenter Trial to
Assess an Everolimus-Eluting Coronary Stent Sys-
tem [PROMUS Element] for the Treatment of Up to
Two de Novo Coronary Artery Lesions trial), which
assessed patients with low-to-moderate cardiovas-
cular event risk, has previously demonstrated non-
inferiority of the Promus Element stent as compared
with the second-generation Xience V/Promus stent
(Abbott Vascular/Boston Scientiﬁc) (13), showing
a favorable rate of the primary endpoint target
lesion failure (5.9%) for Promus Element after
3 years (14). The HOST-ASSURE trial (Harmonizing
FIGURE 1 Kaplan-Meier Curves for TVF and the Individual Components at 2-Year Follow-Up
Kaplan-Meier cumulative incidence curves for: (A) the primary endpoint target vessel failure (TVF), a composite of cardiac death, target vessel–related myocardial
infarction, or target vessel revascularization; (B) cardiac death; (C) target vessel–related myocardial infarction; and (D) target vessel revascularization for patients treated
with Resolute Integrity zotarolimus-eluting stents (ZES) or Promus Element everolimus-eluting stents (EES).
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894Optimal Strategy for Treatment of coronary artery
stenosis - sAfety & effectiveneSS of drug-elUting
stents & antiplatelet REgimen trial) has compared
Promus Element with the second-generation Re-
solute stent in South Korean patients in coronary
vessels >2.5 mm in diameter, showing a similar
clinical performance of both stents at 1 year (5). So
far, the SORT-OUT VI all-comers trial (Scandinavian
Organization for Randomized Trials with clinical
OUTcome VI trial) is the only other randomized
study that has also examined the Resolute Integrity
stent, showing at 1 year an incidence of the primary
endpoint of major adverse cardiac events that
was similar to the comparator, the bioresorbable
coating-based BioMatrix Flex stent (Biosensors,
Singapore) (5.3% vs. 5.1%) (6).CHEST PAIN FOLLOWING PCI. Chest pain, the
principal symptom of angina pectoris, is the main
trigger for patients to consult medical professionals
following a successful PCI procedure, and it is fre-
quently associated with further cardiac assessment
and increased costs (8). The prevalence and recurrence
of angina pectoris after coronary revascularization had
previously been investigated in randomized studies
that compared balloon angioplasty with coronary
bypass surgery (22,23) or with PCI, using bare-metal
stents (24,25). However, randomized trials with
DES were mostly focused on device-oriented end-
points (26). Nowadays, there is a growing interest
in the assessment of angina pectoris following the
implantation of novel DES and bioresorbable scaf-
folds (7). But so far, there is a lack of published data
FIGURE 2 Subgroup Analysis: TVF at 2-Year Follow-Up
Target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel
revascularization. CI ¼ conﬁdence interval; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RVD ¼ reference vessel
diameter; other abbreviations as in Figure 1.
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generation DES.
In the DUTCH PEERS trial, there was no difference
in chest pain between the 2 stent arms at both 1- and
2-year follow-up. More than 80% of our patients were
entirely free from chest pain. This rate is similar to or
higher than the prevalence of angina in several
studies with bare-metal stents or DES, reporting 66%
to 79% of the patients to be angina-free at 1 year
(7,27–30). However, none of these studies applied the
highly-deliverable DES that were used in DUTCH
PEERS. A substudy of the FREEDOM trial (the Future
REvascularization Evaluation in patients with Dia-
betes mellitus: Optimal management of Multivessel
disease trial), which assessed diabetic patients with
multivessel disease being treated with PCI or CABG,
found 79.5% and 81.0% of patients to be free fromangina at 1- and 2-year follow-up after PCI with ﬁrst-
generation sirolimus-eluting stents (27), but this
excellent result may be partly attributed to the gen-
eral lower incidence of angina in diabetic patients. In
the SYNTAX trial (The SYNergy between percuta-
neous coronary intervention with TAXus and cardiac
surgery trial), which assessed angina after PCI for
the treatment of 3-vessel or left-main coronary dis-
ease with ﬁrst-generation paclitaxel-eluting stents,
71.6% of patients were free from angina at 1-year
follow-up (28).
The 2 aforementioned studies used the Seattle
Angina Questionnaire, which is a validated method to
assess anginal stability and frequency, physical limi-
tation, treatment satisfaction, and disease perception
by use of a list of standardized questions (31). This
approach requires patients to answer a considerable
FIGURE 3 Cumulative Incidence of Deﬁnite or Probable Stent Thrombosis
The symbols indicate the hierarchically highest adverse events associated with stent thrombosis. Black symbols signify deﬁnite stent
thrombosis. Green symbols signify probable stent thrombosis. *Off-DAPT indicates stent thrombosis in patients not on dual antiplatelet
therapy (DAPT), which consisted of aspirin $80 mg daily and an adequate dose of a P2Y12 receptor antagonist (generally clopidogrel 75 mg
daily). Abbreviations as in Figure 1.
TABLE 3 Outcome Differences Between 1- and 2-Year Follow-Up
Resolute
Integrity ZES
Promus
Element EES Difference (95% CI) p Value
Death
Any cause 1.2 (11/883) 1.3 (12/893) 0.10 (1.03 to 1.23) 0.86
Cardiac cause 0.8 (7/893) 0.8 (7/883) 0.01 (0.91 to 0.94) 0.98
Target vessel–related myocardial infarction 0.2 (2/864) 0.5 (4/881) 0.22 (0.45 to 0.95) 0.69
Target vessel revascularization, clinically indicated 2.1 (18/860) 2.1 (18/867) 0.02 (1.43 to 1.39) 0.98
Target lesion revascularization, clinically indicated 1.6 (14/864) 1.4 (12/873) 0.25 (1.48 to 0.96) 0.67
Target lesion failure* 2.4 (20/847) 2.2 (19/862) 0.16 (1.64 to 1.31) 0.83
Target vessel failure† 2.7 (23/843) 2.8 (24/856) 0.08 (1.54 to 1.69) 0.93
Major adverse cardiac events‡ 3.0 (25/847) 3.4 (29/861) 0.42 (1.29 to 2.13) 0.62
Patient-oriented composite endpoint§ 3.7 (30/821) 5.0 (42/833) 1.39 (0.60 to 3.41) 0.17
Stent thrombosis
Deﬁnite 0.5 (4/880) 0.2 (2/887) 0.23 (0.96 to 0.43) 0.41
Deﬁnite or probable 0.6 (5/879) 0.2 (2/886) 0.34 (1.12 to 0.33) 0.29
Values are % (n/N) or % difference (95% CI). Analyses were performed among survivors of the ﬁrst year of follow-up who did not experience the respective adverse event
during 1-year follow-up. *Target lesion failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically-indicated target lesion revascularization.
†Primary endpoint target vessel failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically-indicated target vessel revascularization. ‡Major
adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, or clinically-indicated target lesion revascu-
larization. §Patient-oriented composite endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization.
Abbreviations as in Tables 1 and 2.
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FIGURE 4 Patient-Reported Chest Pain at 1 and 2 Years
Patient-reported chest pain was classiﬁed into 4 scores: 0 ¼ no chest pain at all; 1 ¼ chest pain only during most severe physical exertion;
2 ¼ chest pain at moderate physical effort (during moderate/normal daily activities); and 3 ¼ chest pain during mild physical exertion or at rest.
(A and B) Information about the presence and extent (i.e., pain score) of chest pain at 1- and 2-year follow-up in all (surviving) patients who
provided chest pain information at the 2 individual time points (n ¼ 1,647 and n ¼ 1,606 patients, respectively). (C) Change in chest pain score
between 1- and 2-year follow-up in 1,572 patients who were alive at 2-year follow-up and answered the chest pain questionnaire both times.
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PERSPECTIVES
WHAT IS KNOWN? For Resolute Integrity and
Promus Element stents, no outcome data beyond
1-year were available from a randomized clinical trial
in all-comers.
WHAT IS NEW? The present 2-year results of the
DUTCH PEERS (TWENTE II) trial provide a safety
signal, as treatment with these drug-eluting stents
showed no late catch-up in adverse events (e.g., stent
thrombosis or repeat revascularization), despite the
cessation of dual-antiplatelet therapy after 12 months
in the vast majority of patients. As patient satisfaction
after coronary revascularization is closely related to
the achievement of a lasting absence of chest pain, we
assessed patient-reported chest pain and found that 2
years after interventions with the study stents almost
9 of 10 patients were not limited by chest pain in their
daily activities.
WHAT IS NEXT? Long-term follow-up of the
DUTCH PEERS trial will not only monitor and carefully
assess very late adverse clinical events after the im-
plantation of these modern durable polymer-coated
stents, but will also help to build a standard of com-
parison with the clinical results of biodegradable
vascular scaffolds, which at present require >1 year
for complete resorption.
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898number of questions, which might sometimes have
a negative effect on the overall response rate of a
study (32).
In the present study, we did not assess angina, but
we scored the patient-reported chest pain in relation
to the individual range of physical activities of a
patient. Although this approach does not attempt to
distinguish between angina and atypical chest pain,
it tackles the key issue of “patient satisfaction,”which
is greatly independent of the classiﬁcation of chest
pain into angina or atypical chest pain (26). We
assessed whether an individual patient felt chest pain
during (individually graded) levels of physical activity,
as this will generally determine whether a patient
seeks further medical advice and/or repeat cardiac
assessment. Notably, we found a signiﬁcant relation
between chest pain at 1-year follow-up and repeat
clinically-indicated TVR during the second year of
follow-up.
STUDY LIMITATIONS. We did not pre-specify the
analysis of the primary endpoint TVF across the
various subgroups; to avoid subjectivity, we applied
subgroup deﬁnitions of previous DES trials (2,3).
Rigorous embracing of the principle of ischemia-
driven PCI may have contributed to the relatively
low rate of residual chest pain following PCI with
novel newer-generation DES in DUTCH PEERS.
Knowledge on the completeness of coronary revas-
cularization would have facilitated the interpreta-
tion of the chest pain data, but similar to most
other all-comer DES trials, DUTCH PEERS did not
assess this matter. It is desirable that future ran-
domized clinical trials prospectively address this
issue.
CONCLUSIONS
During the second year of follow-up, the incidence of
adverse clinical endpoints remained similar and low
for both DES. The vast majority of patients were free
from chest pain after 1 and 2 years.
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